INVESTMENTS IN ASSOCIATES (Tables)

12 Months Ended

Aug. 31, 2019

Disclosure of associates [abstract]

Disclosure of detailed information about carrying value of investments in associates [Table Text Block]

		ALPHA-CANNABIS			EVIANA HEALTH			HYASYNTH
		PHARMA GMBH			CORPORATION			BIOLOGICALS INC.
		(A)			(B)			(C)			TOTAL
Participating share (1)		25.0%			19.9%			43.4%
Balance, September 1, 2018	$	-		$	-		$	-		$	-
Additions		3,408			5,000			5,000			13,408
Transaction costs		160			73			89			322
Distributions		-			(374	)		-			(374	)
Share of net income (loss)		(50	)		(734	)		(477	)		(1,261	)
Impairment loss		-			(950	)		-			(950	)
Foreign currency translation gain (loss)		(22	)		(15	)		-			(37	)
Balance, August 31, 2019 (2)	$	3,496		$	3,000		$	4,612		$	11,108

Note 1: % Interest includes the potential ownership interest that could result from the conversion of debentures and exercise of warrants

Note 2: OHI utilizes the most recently issued quarterly financial statements of its associates in its results with a two months lag since the Company does not have the same reporting date as its associates (for example, for the period ended August 31, OHI utilizes its associates’ June 30 results)

Disclosure of detailed information current and non-current assets, current and non-current liabilities as well as revenues and net loss of the Company's material investments in equity method investees [Table Text Block]

		EVIANA HEALTH			HYASYNTH
		CORPORATION			BIOLOGICALS INC.
Statement of financial position
Current assets	$	10,024		$	3,223
Non-current assets		3,173			484
Current liabilities		1,329			62
Non-current liabilities (Note 1)		8,290			5,175
Statement of comprehensive loss (Note 2)
Revenue		-			-
Net income (loss) to shareholders		(1,626	)		(1,098	)
Other comprehensive income (loss) to shareholders		(319	)		-
Comprehensive income (loss) to shareholders	$	(1,945	)	$	(1,098	)

Note 1: Non-current liabilities include OHI’s convertible debenture investment at its carrying value of $5,000 and $5,000 (excluding capitalized transaction costs and equity discount), for Eviana Health Corporation and Hyasynth Biologicals Inc., respectively.

Note 2: Net loss is from the date of acquisition to June 30, 2019 as per the associates’ most recently issued quarterly financial statements.